background: Diminished ovarian reserve (DOR) is one of the causes of infertility in young women. In this prospective study, gene expression profiling (GEP) of corona radiata cells (CRC) was performed to identify genes deregulated in DOR patients.
Introduction
The follicular microenvironment is considered as a critical element for the acquisition of oocyte competence which is necessary to support early embryogenesis (Gilchrist et al., 2008) . During folliculogenesis, granulosa cells surrounding the oocyte differentiate into mural granulosa cells, involved in gonadal steroidogenesis, and into cumulus cells, which are closely associated with the oocyte. Within this cumulusoocyte complex (COC), an efficient bidirectional signaling system between the oocyte and surrounding cumulus cells is required for germ cell development (Buccione et al., 1990; Eppig et al., 2002; Gilchrist et al., 2008) . Cumulus cells support the growth and maturation of the oocyte via exchanges of nutrients, growth factors, paracrine signals and secondary messengers, such as Kit ligand, leptin, cAMP and STAT3 (Motta et al., 1994; Antczak and Van Blerkom, 1997; Albertini et al., 2001; Thomas et al., 2005) . Conversely, the oocyte controls the differentiation, proliferation and functions of granulosa cells via the secretion of paracrine factors called oocyte-secreted factors, such as growth differentiation factor-9 (GDF-9) and bone morphogenetic protein (BMP)-15 (Dong et al., 1996; Galloway et al., 2000) .
Corona radiata cells represent the inner layers of follicular cells that directly lie on the zona pellucida and are connected with the oocyte via transzonal cytoplasmic projections, until ovulation. Because of this close interconnectivity, corona radiata cells might be considered as an essential partner of the oocyte. Hussein et al. (2005) have shown that oocyte-secreted factors could act through morphogenetic gradients on cumulus cells, from the inner to the external layers of the follicles. In particular, paracrine factors, such as BMP-15, have been found to prevent follicular cells apoptosis, with the lowest level of apoptosis being observed in corona radiata cells. These findings, as well as results from a study showing that a high proliferative capacity of corona cells was associated with clinical pregnancy (Gregory et al., 1994) , emphasize the importance of a functional cross-talk between the oocyte and corona radiata cells during oogenesis.
Ovarian ageing is characterized by a progressive decrease of follicular ovarian reserve. Diminished ovarian reserve (DOR) defined by a reduced number of ovarian follicles, has been associated with decreased oocyte quality, reduced likelihood of pregnancy, increased miscarriage rates and poor response to ovarian stimulation for IVF (Broekmans et al., 2009) . The prevalence of DOR has been estimated at 10% among infertile women (Scott et al., 1993) . It is currently unclear whether the origin of this decline is related to the oocyte, its follicular microenvironment or both. Oocyte damage, especially through the accumulation of chromosomal abnormalities with increasing maternal age, as well as cumulus cell dysfunctions, could be involved in oocyte quality impairment observed in patients with DOR. Whether the origin of DOR comes from primary dysfunction of an oocyte or cumulus cells, it is likely that these ageing-related modifications will affect cumulus cells. In agreement with this hypothesis, cumulus cells of patients with DOR have been shown to produce less steroids and inhibin, to have a reduced proliferative capacity and to more frequently undergo apoptosis (Seifer et al., 1996a,b) .
As the oocyte and the corona radiata cells interact tightly, this prospective study hypothesized that analyzing corona radiata cells could improve our understanding of DOR pathogenesis. Therefore, a microarray-based gene expression profiling study of corona radiata cells isolated from COCs of women undergoing IVF with ICSI, was first conducted in order to identify genes differentially expressed between patients with normal ovarian reserve (NOR) and those with DOR. On the basis of a selected subset of those differentially expressed genes, a microfluidic-based quantitative RT -PCR (qRT-PCR) assay was subsequently used on an independent set of patients, to validate the microarray-derived results and to refine more precisely the molecular deregulations occurring at the gene level in patients with DOR.
Materials and Methods

Characteristics of the patients
Corona radiata cells were obtained from 48 patients undergoing IVF with ICSI in Angers University Hospital ART center between January and December 2010. Criteria used for patients' selection were plasma antiMüllerian hormone (AMH), FSH and estradiol (E 2 ) levels as well as ovarian ultrasonography with antral follicle count (AFC) (de Carvalho et al., 2008) . Except for AMH, all other measures and the ultrasonography examinations were performed on Day 3 of a spontaneous cycle. Patients were considered to have NOR if they had: AMH level above 2 ng/ml, FSH level below 8 IU/l, E 2 level below 60 pg/ml and an AFC above 4 per ovary. Patients were considered to have DOR if they had an AMH level below 2 ng/ml and/or an AFC below 5 per ovary. Patients with an ovarian dystrophy profile defined by an AFC above 10 per ovary, with small follicles encircling the ovarian cortex, were excluded from this study. All participants gave their written informed consent, and the study was approved by the Local Ethical Committee of Angers University Hospital (reference: CB 2010-06).
A first group of eight patients was considered for the microarray study, of whom four had NOR and four had DOR. A second group of 40 patients was considered for the validation phase (patients with NOR, n ¼ 20, patients with DOR, n ¼ 20). Characteristics of these 40 patients as well as the procedures used for suppression of pituitary gonadotrophin release and follicular growth stimulation are summarized in Table I . In all cases, ovulation was induced with hCG, 5000 IU (MSD, Whitehouse Station, NJ, USA), and oocytes were retrieved using a transvaginal probe. As expected, the doses of FSH used for the stimulation phase were higher in patients with DOR. There was no significant difference in term of distribution with respect to the drugs used for LH suppression and ovarian stimulation between patients with NOR and those with DOR (Table I) .
Isolation of corona radiata cells
COCs were retrieved 36 h after hCG treatment and washed in multiple dishes with Flushing medium (Origio-France, Limonest, France) to eliminate the remaining mural granulosa cells, blood cells and cellular debris. COCs were subsequently incubated for 1 h at 378C in Ferticult culture media (Fertipro, Beernem, Belgium) . For each patient, cumulus cells were discarded using hyaluronidase (80 IU, Fertipro) and gentle pipetting with a 140 mm diameter stripper pipette (Origio-France). All oocytes with their remaining corona radiata were transferred in 1 ml of Ferticult, and corona radiata cells were separated from the oocyte by gentle pipetting with a 125 mm diameter stripper pipette. Metaphase II (MII) oocytes were used for ICSI procedure. For each patient, pooled corona radiata cells were centrifuged at 2000g for 10 min. The supernatant was removed and the pellet immediately frozen in liquid nitrogen until nucleic acid extraction. The median number of COCs retrieved per woman was lower in patients with DOR than in those with NOR. The percentage of immature oocytes (all but MII oocytes) was not significantly different between these two groups of patients (Table I) .
RNA extraction and quantification
Total RNA extraction was carried out using the Nucleospin RNA XS kit (Macherey-Nagel, Düren, Germany) which included a DNAse digestion step. Isolated RNA was eluted in 15 ml RNAse-free water. Total RNA quantification was performed using the Nanodrop ND-1000 spectrophotometer ( 
Microfluidic-based qRT-PCR assay
Seventeen gene transcripts were assessed, including POLR2A, which was considered as the reference gene.
cDNA synthesis
First, the RNA of each sample was reverse transcribed using the SuperScript Vilo cDNA synthesis kit (Invitrogen SARL, Cergy Pontoise, France) according to the manufacturers' instructions, using the blend of oligo(dT) and random hexamers.
Primer design
For each gene, a first set of two primers was chosen in consecutive exons spanning a large intron. Exon sequences for primer design were extracted from Ensembl (GRCh37). These pairs were used in the pre-amplification step. A third primer, compatible with one of the first two primers, was designed to encompass both the 5 ′ end and 3 ′ start of consecutive exons to prevent persisting genomic DNA or unspliced intron amplification bias. This pair was used in a second PCR step, i.e. qRT-PCR, on the Biomark (Fluidigm Europe B.V., Amsterdam, Netherlands). For forkhead box C1 (FOXC1), which only contains one exon, the same primer pair designed inside this exon was used for pre-amplification and qRT-PCR. All primers were designed using Primer3 version 0.4.0 (http://frodo.wi.mit.edu/primer3/). Designs were checked for specificity by in silico PCR (http://genome.ucsc.edu/cgi-bin/hgPcr) on genome assembly and genes. Detailed primer sequence information is available in Supplementary data, Table SI. qRT-PCR assays qPCRs were performed on the Biomark (Fluidigm Europe B.V.), in a microfluidic multiplex 48.48 dynamic array chip according to the Fluidigm Advanced Development Protocol with EvaGreen (PN 100-1208 B1). Briefly, a 14-cycle pre-amplification reaction was performed for each sample in 10 ml by pooling all primer pairs (final concentration, 50 nM), 4.5 ml of cDNA and 5 ml of 2PreAmp Master Mix (Life Technologies SAS, Villebon sur Yvette, France) according to the manufacturers' recommendations. For each individual assay, 5 ml of 10 × Assay Mix containing 9 mM forward primer, 9 mM reverse primer and 1 × Assay Loading Reagent were loaded into one of the Assay Inlets on the chip. The following solution was loaded in sample inlets: 1.25 ml of pre-amplified sample previously diluted to 1:5 in low Tris-EDTA (TE) buffer, 2.5 ml of 2 × Taqman Gene Expression Master Mix (Life Technologies SAS), 0.25 ml of 20 × DNA Binding Dye Sample Loading Reagent (PN 100-0388, Fluidigm Europe B.V.), 0.25 ml of 20 × EvaGreen (Biotium, VWR International S.A.S., Fontenay-sous-Bois, France) and 0.75 ml of low TE buffer. The Biomark's default cycling program with a final melting was used to amplify fragments. All experiments were performed in triplicate.
Data analyses
Analysis of microarray data GenomeStudio 2010.3 software (Illumina Inc., San Diego, CA, USA) and its Gene Expression Analysis Module (version 1.8.0) were used for signal extraction and normalization. The quantile normalization method was applied to the primary probe data. Processed probe data were then filtered according to the following criteria: minimal signal intensity fold change of 1.50 across all samples; minimal probe signal intensity absolute change of 150 across all samples and maximal value for probe signal intensity of 50 000 across all samples. Among the 48 803 probes assessed on HumanHT-12 v3 Expression BeadChips, 2979 satisfied these filtering criteria. These filtered data were log-transformed before being analyzed. Cyber-T software (Institute for Genomics and Bioinformatics, University of California, Irvine, USA; http://cybert.ics.uci.edu/) was used to identify statistically significant differentially expressed genes based on a regularized t-test that uses a robust Bayesian estimate of the variance among gene measurements ). This choice was based on the facts that, because of a low number of replicates available for the comparison of NOR versus DOR patients samples, (i) poor estimate of the variance would be obtained with a simple t-test for each gene transcript, (ii) the use of a t-test including a multitesting correction process based on permutations would not be appropriate because of the limited number of significant permutations available with four samples per group, (iii) Bayesian statistical approach using a regularized t-test has been shown to enable identifying more differentially expressed genes with a higher level of global confidence than a simple t-test ). In addition, based on the modeling of P-value distributions, the approach proposed in Cyber-T provided a computational method for estimating experiment-wide false positive and negative levels (Baldi and Hatfield, 2002) . The analysis was performed with the following parameters values within Cyber-T: minimum non-zero replicates required set to 4; selection of the option to perform a posterior probability of differential expression test with a number of beta-fit iterations set to 3; sliding window size for approximating the variance of the values set to 101; confidence value that applies to the Bayesian variance estimate set to 12. Omics Explorer 2.2 software was used for hierarchical clustering and principal-component analyses (PCA), as well as for differential expression analyses based on a simple unadjusted t-test (Qlucore, Lund, Sweden; http://www.qlucore.com). Hierarchical clustering of both samples and transcripts was performed using average linkage method and the Euclidean metric, with each variable being normalized to mean 0 and variance 1. A threshold P-value of 0.01 was used to consider a gene as being differentially expressed between NOR and DOR samples with either a classical or a regularized t-test at this stage of the study.
Analysis of microfluidic-based qRT-PCR data
C t values were obtained using BioMark Gene Expression Data Analysis version 3.0.2 according to Fluidigm's recommendations for EvaGreen Gene Expression. Relative gene expression was calculated via the deltadelta C t method (Livak and Schmittgen, 2001 ). Omics Explorer 2.2 software was used for PCA. NCSS2007
w software (NCSS, Kaysville, USA; http://www.ncss.com) was used to compute Mann-Whitney U-test, with which a threshold P-value of 0.05 was used to consider it as statistically significant.
In silico analyses of transcriptional control of the identified genes through estrogen receptors Four complementary in silico approaches were used to assess whether the genes identified in this study as being differentially expressed between DOR Gr1 and DOR Gr2 patients could be estrogen-responsive genes, by the way of estrogen receptor (ER). First, Dragon Estrogen Responsive Genes Database version 2, a comprehensive and integrated knowledge database was searched (Tang et al., 2004) . Briefly, the search was based on the identification of estrogen response element (ERE) consensus sequences derived from 13 base pair palindrome GGTCAnnnTGACC within the promoter region of the selected genes. Second, the Comparative Toxigenomics Database was used to assess whether the identified genes were known targets of E 2 , ethinyl-E 2 (a semisynthetic alkylated E 2 with a 17-alpha-ethinyl substitution), diethylstilbestrol (a synthetic nonsteroidal estrogen), tamoxifen (a first generation selective ER modulator with estrogen agonist/antagonist functions), 4-hydroxy-tamoxifene or raloxifene (a second generation selective ER modulator with estrogen agonist/antagonist functions) (Davis et al., 2011-http ://ctd.mdibl.org/). Third, the human DNA sequence surrounding each identified mRNA-10 kb upstream and 2 kb downstream of each as well as the corresponding gene sequence were retrieved from the EnsEMBL Database version 64 through the Regulatory Sequence Analysis Tools webportal using the Retrieve EnsEMBL-seq option (http://rsat.ulb.ac.be/rsat/). The size of the DNA region screened for EREs was based on the fact that these elements could be located at distant sites from the transcription start site (Bourdeau et al., 2004; Deschênes et al., 2007) . A search for the palindromic sequence GGTCAnnnTGACC was then performed within each of these upstream, within and downstream sequences using the Pattern Matching 'DNA pattern' and International Union Pure and Applied Chemistry search option and the default parameter settings, except for the number of allowed substitutions that was set to 2 (see detail of the queries in supplementary File). Fourth, a search was also performed within the University of California Santa Cruz Genome Browser to identify whether some of these genes were potentially direct targets of ERs, either because of the presence of a conserved binding site sequence for ER-alpha or -beta, or because of ChIP-seq data from the ENCODE project showing that ER alpha was able to bind to regions surrounding (or within) the studied genes in ECC-1 (a steroid-responsive endometrial cell line expressing ER alpha and beta, as well as progesterone and androgen receptors - Mo et al., 2006) , TD-47 (an ER-positive breast cancer cell line) or both cell lines (Fujita et al., 2011; Rosenbloom et al., 2010 ; http://genome.ucsc.edu/cgi-bin/hgGateway/).
Results
Identification of genes differentially expressed in NOR and DOR patients
Gene expression profiles of corona radiata cells from four patients with DOR were compared with those of corona radiata cells obtained from four patients with NOR. Among the 2979 transcripts that were considered for this analysis, 115 were identified as being differentially expressed between the NOR and DOR groups (Supplementary data, Table SA and Fig. SA ) using a Bayesian t-test approach (transcripts up-regulated in patients with NOR, n ¼ 33 -transcripts up-regulated in patients with DOR, n ¼ 82). Forty-eight of these differentially expressed transcripts were characterized by a posterior probability of differential gene expression of at least 0.90 meaning that less than five false positives should be expected -, including AMH type II receptor (AMHR2), CXXC finger protein 5 (CXXC5), FOXC1, interferon-inducible guanylate-binding protein 2 (GBP2), plateletderived endothelial cell growth factor (ECGF1, also called thymidine phosphorylase, TYMP), latexin (LXN) and zinc finger MIZ-domain containing 1 (ZMIZ1), which were expressed at significantly higher levels in the NOR group, as well as CBP/p300 interacting transactivator 2 with GLU/ASP-rich C-terminal domain 2 (CITED2), connective tissue growth factor (CTGF), growth arrest-specific 1 (GAS1), insulin receptor substrate 2 (IRS2), prostaglandin-endoperoxide synthase 2 (PTGS2), parathyroid hormone-like hormone (PTHLH), suppressor of cytokine signaling 2 (SOCS2) and versican (VCAN, also called chondroitin sulfate proteoglycan 2, CSPG2), which were expressed at significantly higher levels in the DOR group (Fig. 1 ). According to a threedimensional PCA based on those 48 differentially expressed genes, the cumulative percentage of variance accounted for by the first three components was 89% (Supplementary data, Fig. SB ). Of note, using a simple t-test, without any adjustment for multitesting, 84 genes were found to be differentially expressed between the NOR and DOR groups, including AMHR2, CXXC5, FOXC1, GBP2, ECGF1/TYMP, LXN, ZMIZ1, CITED2, CTGF, GAS1, IRS2, PTGS2, PTHLH, SOCS2, as well as follistatin-like 3 (FSTL3) (Supplementary data, Fig. SC) .
Identification of two subgroups of patients with DOR
A validation step using microfluidic-based qRT-PCR assays was subsequently performed, involving a larger independent group of 40 consecutive female patients (n ¼ 20 patients with NOR, n ¼ 20 patients with DOR). Six of the 16 genes considered for validation were confirmed as being differentially expressed between the NOR and DOR groups (Table II) . CXXC5 and FOXC1 were significantly over-expressed in patients with NOR, whereas CTGF, FSTL3, PTGS2 and SOCS2 were significantly over-expressed in patients with DOR (Fig. 2) . No significant correlations were observed between the expression level of those six differentially expressed genes and either the baseline FSH level of the studied patients or the dose of FSH these patients received during the stimulation phase (Supplementary data, Fig. SD and E) . Using the qRT-PCR data from these six transcripts, a PCA was performed in order to identify more homogeneous subgroups of patients. This approach enabled the identification of a subgroup of 10 patients (9 having DOR), who behaved differently from the other patients with respect to these six transcripts (Fig. 3 Top) . This finding led us to consider two separate subgroups of patients with DOR, namely, DOR Gr1 and DOR Gr2. DOR Gr2 subgroup included the nine patients with DOR identified by the PCA. DOR Gr1 subgroup included the 11 remaining patients with DOR, mixed with those having NOR (except NOR patient c124 who clustered with DOR Gr2 patients; Figure 3 Bottom). Eleven out of the 16 genes quantified by qRT-PCR assays were identified as being differentially expressed between DOR Gr1 and DOR Gr2 subgroups. CXXC5, FOXC1, GBP2 and ZMIZ1 were expressed at significantly lower levels in DOR Gr2 patients, whereas CITED2, CTGF, GAS1, IRS2, PTGS2, SOCS2 and VCAN were expressed at significantly higher levels in DOR Gr2 patients (Fig. 4, Table III , Supplementary data, Fig. SD, SF) . Moreover, and in agreement with the results of the PCA, in DOR Gr1 patients, the expression levels of those 11 genes were not different from the ones observed in women with NOR (data not shown).
Estrogen-responsive gene profiles distinguish two subgroups of patients with DOR
When comparing DOR Gr1 and DOR Gr2 patients according to their clinical and biological characteristics, the only covariate that enabled distinguishing those two was the baseline E 2 level, which was significantly higher in DOR Gr2 patients (Fig. 5, Supplementary data ,  Table SII ). According to the Dragon Estrogen Response Genes Database version 2, eight of the 11 genes differentially expressed between DOR Gr1 and DOR Gr2 subgroups were considered as estrogenresponsive genes; namely, CITED2, CTGF, FOXC1, GAS1, GBP2, PTGS2, SOCS2 and VCAN. According to the Comparative Toxicogenomics Database, the same eight genes as well as CXXC5 and ZMIZ1 were also identified as transcriptional targets of estrogens or derivatives-such as ethinyl-E 2 , diethylstilbestrol, tamoxifen or raloxifene-(Supplementary data, Table SB). Furthermore, using the Regulatory Sequence Analysis Tools, the palindromic ERE sequence or its derivatives (maximum score allowed 0.85, corresponding to a maximum of two nucleotidic substitutions) were found in all 11 genes when considering the 10 kb of sequence upstream of the Figure 1 Heatmap and two-dimensional hierarchical clustering of the 48 transcripts found to be differentially expressed between patients with NOR and those with DOR, with a minimal posterior probability of differential expression set to 0.90 (microarray experiments). Each column represents a sample. The first four columns represent samples from patients with NOR (C_1 -C_4), the remaining four represent samples from patients with DOR (E_5 -E_8). Each row represents a marker (gene transcript). The log 2 relative gene expression scale is depicted on the top right. Each Bayesian P-value corresponds to the significance level of a regularized t-test. PPDE, posterior probability of differential expression. transcription start site, in all gene sequences except CITED2, and in the 2 kb downstream sequence of CITED2, CTGF, CXXC5, GBP2, SOCS2, VCAN and ZMIZ1 (see details in Supplementary data, Table SC) . Moreover, according to the University of California Santa Cruz Genome Browser/ENCODE project reporting transcription factor ChIP-seq data obtained from the ECC-1 and/or TD-47 cell lines, ER-alpha binding sites were identified either upstream of the transcription start site and/or within the gene sequence and/or downstream of the gene sequence, for CITED2, CTGF, CXXC5 and ZMIZ1 (Supplementary data, Table SD). Finally, using the same genome browser, transcription factor binding sites for ER-alpha, conserved in both human/mouse/rat alignments, were also identified upstream of, within or downstream of CITED2, CXXC5, CTGF, FOXC1, SOCS2 and ZMIZ1 sequences (Supplementary data, Table SE ). Overall, these in silico analyses suggested that most, if not all, of the 11 genes, which enabled distinguishing DOR Gr1 from DOR Gr2 patients, were likely to be transcriptional targets of estrogens (Table IV) .
Discussion
Although indirect, studying cumulus cells is currently considered as one of the most promising approaches to assess oogenesis and oocyte quality. Microarray-based gene expression profiling, which represents nowadays a powerful tool in the genomic area, enables researchers to quantify the expression levels of thousands of genes, simultaneously, on multiple samples. This genome-wide approach, performed on the entire cumulus surrounding the oocyte, has already led to the identification of markers associated with oocyte maturity ( (Assou et al., 2008; Hamel et al., 2008; Wathlet et al., 2011) . Limited data are available regarding a cumulus cell-derived gene expression signature which is associated with DOR (Chin et al., 2002) . Because of the tight interconnections between the oocyte and corona radiata cells, our study focused on the characterization of the latter in patients with DOR. First using microarraybased gene expression profiling, 48 markers were identified as being differentially expressed between NOR and DOR patients. According to their biological relevance, based on data available in the literature, 16 of these genes were chosen for a validation step to be performed on a larger group of 40 patients with NOR or DOR. As low numbers of cells were to be obtained, microfluidic-based qRT-PCR assays were used to form RNA quantification. Therefore, 6 of these 16 transcripts (i.e. CTGF, CXXC5, FOXC1, FSTL3, PTGS2 and SOCS2) were confirmed as being differentially expressed between patients with NOR and those with DOR.
FOXC1 gene was among the genes identified as being downregulated in patients with DOR. This member of the forkhead box transcription factor family, which plays a critical role in cell differentiation as well as in the development of many organs, was considered as a candidate for further studies as, in mouse, Foxc1 null mutants were characterized by an abnormal development of the gonads (Mattiske et al., 2006 Diminished ovarian reserve and gene expression profiling ovaries from mutant embryos into ovariectomized females was associated with normal folliculogenesis up to pre-antral stages, no follicles developed beyond early antral stages (Mattiske et al., 2006) . In addition, Uhlenhaut et al. (2011) have recently highlighted the involvement of the forkhead box transcription factor family in regulating mouse and human folliculogenesis, both at the oocyte and the granulosa cell levels. CXXC5 gene was the second consistently down-regulated gene in all our patients with DOR. CXXC5 was considered for validation because of its role in developmental processes through (i) its ability to interact with disheveled and inhibit the wingless type MMTV integration (WNT)/beta-catenin signaling pathway (Kim et al., 2010) , and (ii) its induction in rat neural stem cells by BMP-4 (Andersson et al., 2009) , a member of the transforming growth factor (TGF)-beta superfamily also involved in ovarian primordial follicular development and primordial-to-primary follicle transition (Knight and Glister, 2006; Childs et al., 2010) . FSTL3, which belongs to the family of extracellular matrix-associated glycoproteins called follistatin-module proteins, was also expressed at significantly lower levels in patients with DOR when using a simple unadjusted t-test. This gene was also considered for validation as, in transgenic mouse models, it regulates gonadal development and gametogenesis by a local inhibition of activin paracrine activity and related factors, such as BMP-2 . Interestingly, these mice displayed a reduced number of antral follicles with an increased rate of follicular atresia. In addition, FSTL3 has been shown to modulate the action of inhibins and tumor growth factor-beta superfamily members (Tsuchida et al., 2000; Schneyer et al., 2004) . As such, FSTL3 has the ability to neutralize inhibin A and BMPs, including BMP-4 (Schneyer Figure 2 Expression levels of the six gene transcripts found to be differentially expressed between patients with NOR and those with DOR using microfluidic-based qRT-PCR assays. Expression levels of each gene are presented using box plots, separating the NOR or DOR groups. The horizontal line in the interior of the box is located at the median of the data. The height of the box is equal to the interquartile distance, which is the difference between the third and first quartiles of the data. The interquartile distance indicates the spread of the distribution for the data. The whiskers (the lines extending from the bottom and the top parts of the box) go to the nearest value not beyond the span from the quartiles, i.e. 1.5 times the interquartile distance from the center of the data. Points above or below the whiskers are considered outliers and are drawn individually (indicated by circles).
et al. Sidis et al., 2006) . SOCS2, which was up-regulated in patients with DOR, was also considered for validation as it is a critical negative regulator of the insulin-like growth factor (Igf)-1 signaling pathway (Metcalf et al., 2000) that has been associated with granulosa cell proliferation and follicular growth in mature murine ovaries. In Igf1 knock-out mouse, ovarian follicles were arrested at an early developmental stage (Zhou et al., 1997; Kadakia et al., 2001) . Furthermore, lack of Socs-2 expression in female mice results in poor reproductive performance (Horvat and Medrano, 2001 ). The CTGF, up-regulated in patients with DOR, was also selected, as (i) in rats, its expression has been associated with primordial follicle assembly as well as with primordial-to-primary follicle transition Schindler et al., 2010) , (ii) during normal granulosa cells maturation, its expression level increased from small pre-antral follicles to large antral follicles (Harlow et al., 2007) , (iii) in the cumulus oophorus of pre-ovulatory follicles, a mural-to-antral CTGF gradient has been observed, with the highest CTGF expression being detected in proximity to the oocyte (Harlow et al., 2007) and (iv) CTGF has been shown to antagonize BMP-4 activity and activates TGFB signaling pathway (Abreu et al., 2002) . Of note, during granulosa cell maturation, FSH has been shown to down-regulate CTGF expression, whereas TGFB1, GDF-9 and activin A had the opposite effect in undifferentiated granulosa cells (Slee et al., 2001; Harlow et al., 2002 Harlow et al., , 2007 Liu et al., 2002) . Finally, PTGS2, or cyclooxygenase-2, which catalyzes the first rate-limiting step in the production of prostaglandins E 2 and F2 alpha and was up-regulated in patients with DOR, was also considered as its expression has been associated with cumulus expansion and maturation as well as with oocyte competence and higher quality embryos (Hizaki et al., 1999; McKenzie et al., 2004; Takahashi et al., 2006; Gershon et al., 2007) . In addition, within the COC, PTGS2 expression has been shown to be under the control of GDF-9 (Elvin et al., 1999 (Elvin et al., , 2000 , one of the main oocyte-secreted factors controlling the growth and differentiation of granulosa cells (Carabatsos et al., 1998; Elvin et al., 1999) . Finally, VCAN, which encodes a major CSPG of the extracellular matrix, was also selected as it has already been shown that high VCAN expression levels in cumulus cells were associated with a higher developmental potential with (i) enhanced implantation rates and greater developmental capacity throughout gestation (Gebhardt et al., 2011) , (ii) higher pregnancy rates following ICSI procedures and (iii) oocyte maturity (Adriaenssens et al., 2010) . To explain the discrepancy between the results obtained with microarrays and microfluidic-based qRT-PCR assays, it was hypothesized that the gene expression profiling study, based on a limited number of patients, might have focused the first analysis on a subset of patients with DOR, whereas the validation group was more widely reflecting the real population heterogeneity of those patients. Therefore, a PCA was performed using the data from the six transcripts found to be differentially expressed between DOR and NOR patients using both approaches. PCA enabled the identification of two subgroups of patients with DOR, patients belonging to DOR Gr1 subgroup being mixed with those having NOR. Six additional transcripts (CITED2, GAS1, GBP2, IRS2, VCAN and ZMIZ1), which were identified as being differentially expressed during the microarray data analysis, were also differentially expressed between these two subgroups of DOR patients using microfluidic-based qRT-PCR assays.
In order to explain the fact that gene expression profiling data identified two subgroups of DOR patients, their clinical and biological characteristics were compared. Except the fact that DOR Gr2 patients had significantly higher baseline E 2 levels than DOR Gr1 patients, no differences were observed between these two subgroups of DOR patients, whether considering their age, AMH and FSH baseline levels, AFCs, stimulation protocol used, total FSH dose administrated during stimulation or other characteristics. Whether a direct or indirect relationship exists between baseline E 2 level and the expression level of the 11 differentially expressed genes remains speculative. One could hypothesize that some patients with DOR behave differently in terms of E 2 metabolism or activation of estrogen-related signaling pathways. Previous studies, in various models, have indeed reported that estrogens-or derivatives-could modify the expression level of some of the genes identified as being differentially expressed between DOR subgroups, including CTGF, IRS2, PTGS2, SOCS2 and VCAN ( components in a principal-components analysis of samples obtained from patients with NOR and patients with DOR according to the six transcripts which were differentially expressed (microfluidic data). (Bottom) Identification of two subgroups of patients with DOR, i.e. DOR Gr2 (n ¼ 9) and DOR Gr1 (n ¼ 11), the second subgroup being mixed, with all but one of the patients having NOR. Patient c124, with NOR, was localized with DOR Gr2 patients. For both pictures, first, second and third components represent 50, 18 and 13% of the variance, giving a cumulative percentage of variance of 81%. Each sample is connected by lines to the two most similar samples according to Euclidian distances. Samples are color-coded as indicated.
Diminished ovarian reserve and gene expression profiling Xie et al., 2003; Leong et al., 2004; Tamura et al., 2004; Harlow et al., 2007; Hamilton et al., 2008; Bu et al., 2009; Pandey et al., 2009; Salgado et al., 2009; Waclawik et al., 2009) . In agreement with this hypothesis is the fact that the in silico analyses suggested that most, if not all, of the 11 differentially expressed genes were likely to be estrogen-responsive genes. One could also consider that DOR Gr1 and DOR Gr2 subgroups represent DOR patients assessed at different time points along the evolution of ovarian reserve decline, DOR Gr2 patients being evaluated at a more advance stage. It has been shown that during ovarian aging a selective rise of inter-cycle FSH level was occurring following quantitative alterations of the ovarian reserve, as assessed by AFC and AMH level (Broekmans et al., 2009) . This endocrine modification has been shown to induce a premature-or accelerated-recruitment of antral follicles with an early increase of E 2 secretion by granulosa cells (Klein et al., 2002; van Zonneveld et al., 2003; Broekmans et al., 2009 ). Therefore, DOR Gr2 patients' profile could be related to the fact that these patients were evaluated at a more advanced stage, the higher E 2 levels being related to an earlier follicle recruitment in these patients (compared with DOR Gr1 subgroup). The progressive increased, or decreased, expression levels of some of the identified genes (especially for CTGF, FOXC1, FSTL3 and GBP2), observed from NOR to DOR Gr1, then to DOR Gr2 patients, was in agreement with the hypothesis of a continuum between these three groups of patients. This hypothesis is reinforced by data for patient c124, who was initially considered with NOR, based on her AFC and AMH values. However, according to the results of the PCA, this patient behaved like those in the DOR Gr2 subgroup. This woman, indeed, at a previous assessment, was suspected to have polycystic ovary syndrome (PCOS), according to her response following FSH stimulation. According to her gene expression profile, patient c124 should have been considered as having DOR rather than NOR. This discrepancy between her gene expression Figure 4 Expression levels of the 16 transcripts quantified by microfluidic-based qRT-PCR assays, including the 11 found to be differentially expressed in DOR Gr1 and DOR Gr2 patients (white box plots). Expression levels of each gene are presented using box plots, for the NOR group (excluding patient c124), and DOR Gr1 and DOR Gr2 subgroups. (See Fig. 2 legend for description of box plots.) Gray box plots were used for genes that were not differentially expressed between DOR Gr1 and DOR Gr2 patients.
profile and normal AFC and AMH level could be explained by the fact that patients with PCOS have a high AFC and AMH level, whereas patients with DOR are characterized by low AFC and AMH level.
Therefore, a patient having both PCOS and DOR, such as patient c124, could be expected to have normal AFC and AMH level. Tehrani et al. (2010) have already proposed that PCOS may be a protective factor against ovarian aging. Although limited to a single case, the present study suggests that, despite a normal ovarian balance, as assessed by AFC and AMH level, the genes identified as being deregulated in DOR Gr2 patients could also be deregulated in women having both PCOS and DOR.
Several studies have underlined the critical role of TGFB superfamily members in the intra-ovarian control of follicular growth and maturation; including AMH, BMP-2,4, 5, 6, 7 and 15, GDF-9 and activins, as well as TGFA and TGFB and SMAD family members (SMAD2, SMAD3, SMAD4) (Knight and Glister, 2006; Trombly et al., 2009) . It is noteworthy that CITED2, CTGF, FOXC1, FSTL3, GAS1, IRS2, PTGS2, SOCS2, VCAN and ZMIZ1 have all been associated, either as targets or regulators, with at least one of these signaling pathways, suggesting that their deregulation might be of importance in patients with DOR (Kähäri et al., 1991; Elvin et al., 1999; Tsuchida et al., 2000; Bartholin et al., 2002; Zhou et al., 2002; Harlow et al., 2002; Huang et al., 2004; Chou and Yang, 2006; Li et al., 2006; Norian et al., 2009) . Interestingly, half of those genes-CTGF, FOXC1, IRS2, PTGS2 and VCAN-have been associated with the epithelial-to-mesenchymal transition or with the reverse process, i.e. the mesenchymal-to-epithelial transition, which is characterized by a transition between motile mesenchymal cells and arrays of tightly attached epithelial cells (Zeisberg et al., 2003; Burns et al., 2006; Bard et al., 2008; Gressner and Gressner, 2008; Neil et al., 2008; Kalluri and Weinberg, 2009; Polyak and Weinberg, 2009; Sheng et al., 2006; Thiery and Sleeman, 2006; Carew et al., 2011 Diminished ovarian reserve and gene expression profiling follicular epithelium arises through a mesenchymal-epithelial transition, indeed, and mesenchymal-epithelial interactions are known to facilitate the primordial-to-primary follicle transition (Bukovsky et al., 2005; Kezele et al., 2005) . Therefore, our study suggests that a deregulation of this trans-differentiation program could exist in patients with DOR. Interestingly, TGFB is a master regulator of the epithelialto-mesenchymal transition (Kaartinen et al., 1995; Zavadil et al., 2001; Thiery and Sleeman, 2006; Ahmed et al., 2007; Thiery et al., 2009; Zhu et al., 2010) . Functional studies will be required to more precisely assess the role of these genes and to confirm if patients with DOR display a deregulation of the mesenchymal-to-epithelial transition.
In conclusion, despite the limitations of small sample size, this study (which focused for the first time on corona radiata cells) identified 12 genes as being potentially involved, directly or indirectly, in the physiopathology of DOR. In addition, a subgroup of patients with DOR (DOR Gr2) was identified, which was characterized by high CITED2, CTGF, GAS1, IRS2, PTGS2, SOCS2 and VCAN expression levels, low CXXC5, FOXC1, GBP2 and ZMIZ1 expression levels and by high baseline E 2 levels. The gene expression signatures identified in this study, which allowed us to distinguish these two subgroups of patients with DOR, could reflect differences in E 2 metabolism and/or the fact that their evaluation was performed at different time points in the evolution of the disease. Our study also suggests that one of the abnormalities observed in patients with DOR could be linked to a deregulation of the TGFB signaling pathway leading, in particular, to a dysfunction of the epithelial-to-mesenchymal transition process. Further studies will be required to confirm these results and validate the hypothesis developed in this study. 
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